Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

7-day Antibiotic Treatment is Noninferior to 14 Days in Afebrile Men with UTI

Kunjam Modha, MD, FACP, SFHM

Dr. Modha

Clinical question: Are 14 days of antibiotic treatment better than 7 days in afebrile men with urinary tract infection (UTI)?

Background: In the era of antibiotic stewardship, a large body of evidence has led to treating various infections (e.g., pneumonia, UTI in women, cellulitis, etc.) with shorter durations of antibiotics. Shorter treatment durations increase compliance, reduce cost as well as adverse effects, and help control the emergence of antibiotic resistance.

Study design: Randomized, double-blind, placebo-controlled, noninferiority trial

Setting: Two U.S. Veterans Affairs medical centers in Minneapolis and Houston

Synopsis: Out of 1,058 eligible men, 272 were randomized. Afebrile men with presumed UTI were treated with 7 days of either ciprofloxacin or sulfamethoxazole-trimethoprim and then randomized to receive either continued antibiotic therapy (n=136) or placebo (n=136) for days 8 to 14 of treatment. The primary outcome was the resolution of UTI symptoms by 14 days of completion of active antibiotic treatment. Secondary outcomes were the recurrence of symptoms and adverse effects of treatment. Symptom resolution occurred in 93.1% in the 7-day group versus 90.42% in the 14-day group (difference, 2.9% which met the noninferiority cut-off). Recurrence of symptoms occurred in 9.9 % in the 7-day group and 12.9% in the 14-day group (p=0.70). Adverse effects occurred in 20.6% of the 7-day group and 23.4% in the 14-day group. Limitations included empiric treatment of UTI in a subset of patients, with pre-treatment urinalysis obtained in 93% of participants and pre-treatment urine culture in 12.1% of participants. Enrollment did not reach the planned 290 participants, thus possibly decreasing study power to identify statistical significance. 

Bottom line: In afebrile men with suspected UTI, treatment with ciprofloxacin or sulfamethoxazole-trimethoprim for 7 days is non-inferior to 14 days with respect to the resolution of UTI symptoms.

Citation: Drekonja DM, et al. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: A randomized clinical trial. JAMA. 2021;326(4):324-31.

Dr. Modha is a staff physician in the department of hospital medicine at the Cleveland Clinic, Cleveland, and an assistant professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University of Medicine. 

  • 7-day Antibiotic Treatment is Noninferior to 14 Days in Afebrile Men with UTI

    April 3, 2023

  • Oral Tebipenem Pivoxil Hydrobromide is Noninferior to IV Ertapenem in Complicated UTI

    April 3, 2023

  • The 7 Deadly Sins for LOS

    April 3, 2023

  • Hospitalist Volunteers Give Back to Their Communities

    April 3, 2023

  • HM and APP Fellowship Benefits

    April 3, 2023

  • How SHM’s DEI Committee Came to Be

    April 3, 2023

  • SIG Spotlight: DEI

    April 3, 2023

  • Chapter Spotlight: North Jersey

    April 3, 2023

  • To Anticoagulate or Not? The Ongoing Dilemma Among CAA Patients

    April 3, 2023

  • Endovascular Therapy for Acute Stroke with a Large Ischemic Region

    April 3, 2023

1 … 74 75 76 77 78 … 984
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences